Shares of AbbVie and Johnson & Johnson took a hit Friday after FDA briefing documents hinted a cheaper competitor for the drug companies’ blockbuster anti-inflammatory treatments could be headed to market soon.

Sections:  business   
Topics:  health   
RELATED ARTICLES
  • no title provided in feed
    Americans' mental health issues are not identified and treated as readily as physical symptoms, especially among children - in part due to a shortage of clinicians. "We're looking for ways to integrate mental health into settings where children and families are every day," says Dr. More
  • no title provided in feed
    Mayor Donna Deegan speaks with CNN's Jake Tapper More
  • no title provided in feed
    Rep. Brad Wenstrup speaks with CNN's Jake Tapper More
  • no title provided in feed
    For some who see a therapist, just talking things through isn't enough. Drama therapy allows the patient to relive a moment or play out their biggest fears. More
  • no title provided in feed
    Sen. Mark Kelly joins The Lead More
  • no title provided in feed
    This year, 28,000 pounds of human waste was removed from base camp. The Mount Everest Biogas Project plans to convert this waste into a usable product. More
BING NEWS:
  • AbbVie Shares Close Down 4.6%, Sees Additional Humira Volume Erosion in 2Q
    By Sabela Ojea Shares of AbbVie lost 4.6% to close at $159.62 on Friday after the company warned about the effects of losing the exclusivity of its ...
    04/26/2024 - 9:39 am | View Link
  • AbbVie Stock Falls As Company Warns of Continued Humira Sales Slump
    Shares of AbbVie ( ABBV) slumped Friday as the pharmaceutical firm warned of deeper declines in sales of its blockbuster arthritis drug, Humira, because of competition from close copies known as ...
    04/26/2024 - 8:04 am | View Link
  • AbbVie's Skyrizi proves a worthy Humira successor with nearly matching sales ahead of potential UC nod
    AbbVie’s immunology heirs Skyrizi and Rinvoq are proving booming growth to make up for once-king Humira’s continuous sales slide. | As Humira continues its sales free fall, newer Skyrizi is proving a ...
    04/26/2024 - 5:06 am | View Link
  • AbbVie Raises Earnings Guidance Even as Humira Sales Continue to Drop
    AbbVie said it expects adjusted earnings in 2024 of between $11.13 and $11.33 a share, up from previous guidance of $10.97 to $11.17 a share. Analysts surveyed by FactSet were expecting full-year ...
    04/26/2024 - 2:58 am | View Link
  • AbbVie’s Q1 earnings beat expectations as arthritis drug boosts growth
    Pharmaceuticals company AbbVie reported its Q1 financial results for 2024 today. AbbVie’s earnings came in at $1.37B, or $0.77 per share.
    04/26/2024 - 1:17 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More News